Cancer Pain – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Cancer Pain – Pipeline Review, H2 2017’, provides an overview of the Cancer Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cancer Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Cancer Pain

The report reviews pipeline therapeutics for Cancer Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Cancer Pain therapeutics and enlists all their major and minor projects

The report assesses Cancer Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Cancer Pain

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Cancer Pain

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alexza Pharmaceuticals Inc

AngioChem Inc

Aoxing Pharmaceutical Company Inc

Aphios Corp

AstraZeneca Plc

ChironWells GmbH

Colby Pharmaceutical Co

ConSynance Therapeutics Inc

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Dompe Farmaceutici SpA

Fujimoto Pharmaceutical Corp

Grunenthal GmbH

Hisamitsu Pharmaceutical Co Inc

Immupharma Plc

Insys Therapeutics Inc

IntelGenx Corp

iX Biopharma Ltd

Klaria Pharma Holding AB

Komipharm International Co Ltd

KPI Therapeutics Inc

Medlab Clinical Ltd

Nanomerics Ltd

Neurocentrx Pharma Ltd

Nippon Kayaku Co Ltd

Orion Corporation

Pain Therapeutics Inc

Pfizer Inc

Pharmaleads SA

Recordati SpA

Ribomic Inc

Trillium Therapeutics Inc

Virobay Inc

WEX Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Cancer Pain - Overview 7

Cancer Pain - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 17

Cancer Pain - Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 21

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Cancer Pain - Companies Involved in Therapeutics Development 28

Alexza Pharmaceuticals Inc 28

AngioChem Inc 28

Aoxing Pharmaceutical Company Inc 28

Aphios Corp 29

AstraZeneca Plc 29

ChironWells GmbH 30

Colby Pharmaceutical Co 30

ConSynance Therapeutics Inc 30

Daewoong Pharmaceutical Co Ltd 31

Daiichi Sankyo Co Ltd 31

Dompe Farmaceutici SpA 32

Fujimoto Pharmaceutical Corp 32

Grunenthal GmbH 33

Hisamitsu Pharmaceutical Co Inc 33

Immupharma Plc 33

Insys Therapeutics Inc 34

IntelGenx Corp 34

iX Biopharma Ltd 35

Klaria Pharma Holding AB 35

Komipharm International Co Ltd 36

KPI Therapeutics Inc 36

Medlab Clinical Ltd 37

Nanomerics Ltd 37

Neurocentrx Pharma Ltd 37

Nippon Kayaku Co Ltd 38

Orion Corporation 38

Pain Therapeutics Inc 39

Pfizer Inc 39

Pharmaleads SA 40

Recordati SpA 40

Ribomic Inc 41

Trillium Therapeutics Inc 41

Virobay Inc 42

WEX Pharmaceuticals Inc 42

Cancer Pain - Drug Profiles 43

(fentanyl + menthol) - Drug Profile 43

(fentanyl + naloxone) - Drug Profile 44

ANG-2002 - Drug Profile 45

AQU-118 - Drug Profile 46

AZD-8797 - Drug Profile 47

Cannabis Intractable - Drug Profile 49

cebranopadol - Drug Profile 50

CPC-111 - Drug Profile 54

crotalphine - Drug Profile 55

CSTI-200 - Drug Profile 56

dexmedetomidine hydrochloride - Drug Profile 57

dronabinol - Drug Profile 60

Drug for Cancer Neuropathic Pain - Drug Profile 61

DWJ-208 - Drug Profile 62

fentanyl - Drug Profile 63

fentanyl citrate - Drug Profile 64

fentanyl citrate - Drug Profile 65

fentanyl citrate ER - Drug Profile 66

gabapentin - Drug Profile 67

HP-3150 - Drug Profile 68

HS-198 - Drug Profile 69

hydromorphone hydrochloride - Drug Profile 70

HYLP-002 - Drug Profile 71

INT-0010 - Drug Profile 72

IPP-102199 - Drug Profile 73

KL-00406 - Drug Profile 74

KL-006 - Drug Profile 75

methadone hydrochloride - Drug Profile 76

Monoclonal Antibodies to Inhibit TRPV1 for Inflammatory Pain and Cancer Pain - Drug Profile 77

NM-127 - Drug Profile 78

PAX-1 - Drug Profile 79

Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous System - Drug Profile 80

Peptide to Target CANP for Cardiovasclar and Cancer Pain - Drug Profile 81

PL-265 - Drug Profile 82

PL-37 - Drug Profile 84

QX-314 - Drug Profile 86

RBM-004 - Drug Profile 87

RBM-007 - Drug Profile 88

resiniferatoxin - Drug Profile 89

saracatinib difumarate - Drug Profile 91

Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 93

Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 94

Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 95

tanezumab - Drug Profile 96

Tetrodotoxin - Drug Profile 100

tilidine hydrochloride - Drug Profile 102

TOT-303 - Drug Profile 103

U-2902 - Drug Profile 104

VBY-825 - Drug Profile 106

zucapsaicin - Drug Profile 107

Cancer Pain - Dormant Projects 109

Cancer Pain - Discontinued Products 112

Cancer Pain - Product Development Milestones 113

Featured News & Press Releases 113

Appendix 120

Methodology 120

Coverage 120

Secondary Research 120

Primary Research 120

Expert Panel Validation 120

Contact Us 120

Disclaimer 121

List of Tables

List of Tables

Number of Products under Development for Cancer Pain, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Cancer Pain – Pipeline by Alexza Pharmaceuticals Inc, H2 2017

Cancer Pain – Pipeline by AngioChem Inc, H2 2017

Cancer Pain – Pipeline by Aoxing Pharmaceutical Company Inc, H2 2017

Cancer Pain – Pipeline by Aphios Corp, H2 2017

Cancer Pain – Pipeline by AstraZeneca Plc, H2 2017

Cancer Pain – Pipeline by ChironWells GmbH, H2 2017

Cancer Pain – Pipeline by Colby Pharmaceutical Co, H2 2017

Cancer Pain – Pipeline by ConSynance Therapeutics Inc, H2 2017

Cancer Pain – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017

Cancer Pain – Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Cancer Pain – Pipeline by Dompe Farmaceutici SpA, H2 2017

Cancer Pain – Pipeline by Fujimoto Pharmaceutical Corp, H2 2017

Cancer Pain – Pipeline by Grunenthal GmbH, H2 2017

Cancer Pain – Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2017

Cancer Pain – Pipeline by Immupharma Plc, H2 2017

Cancer Pain – Pipeline by Insys Therapeutics Inc, H2 2017

Cancer Pain – Pipeline by IntelGenx Corp, H2 2017

Cancer Pain – Pipeline by iX Biopharma Ltd, H2 2017

Cancer Pain – Pipeline by Klaria Pharma Holding AB, H2 2017

Cancer Pain – Pipeline by Komipharm International Co Ltd, H2 2017

Cancer Pain – Pipeline by KPI Therapeutics Inc, H2 2017

Cancer Pain – Pipeline by Medlab Clinical Ltd, H2 2017

Cancer Pain – Pipeline by Nanomerics Ltd, H2 2017

Cancer Pain – Pipeline by Neurocentrx Pharma Ltd, H2 2017

Cancer Pain – Pipeline by Nippon Kayaku Co Ltd, H2 2017

Cancer Pain – Pipeline by Orion Corporation, H2 2017

Cancer Pain – Pipeline by Pain Therapeutics Inc, H2 2017

Cancer Pain – Pipeline by Pfizer Inc, H2 2017

Cancer Pain – Pipeline by Pharmaleads SA, H2 2017

Cancer Pain – Pipeline by Recordati SpA, H2 2017

Cancer Pain – Pipeline by Ribomic Inc, H2 2017

Cancer Pain – Pipeline by Trillium Therapeutics Inc, H2 2017

Cancer Pain – Pipeline by Virobay Inc, H2 2017

Cancer Pain – Pipeline by WEX Pharmaceuticals Inc, H2 2017

Cancer Pain – Dormant Projects, H2 2017

Cancer Pain – Dormant Projects, H2 2017 (Contd..1), H2 2017

Cancer Pain – Dormant Projects, H2 2017 (Contd..2), H2 2017

Cancer Pain – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Cancer Pain, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports